Tuning artificial intelligence on the de novo design of natural-product-inspired retinoid X receptor modulators

Instances of artificial intelligence equip medicinal chemistry with innovative tools for molecular design and lead discovery. Here we describe a deep recurrent neural network for de novo design of new chemical entities that are inspired by pharmacologically active natural products. Natural product characteristics are incorporated into a deep neural network that has been trained on synthetic low molecular weight compounds. This machine-learning model successfully generates readily synthesizable mimetics of the natural product templates. Synthesis and in vitro pharmacological characterization of four de novo designed mimetics of retinoid X receptor modulating natural products confirms isofunctional activity of two computer-generated molecules. These results positively advocate generative neural networks for natural-product-inspired drug discovery, reveal both opportunities and certain limitations of the current approach, and point to potential future developments.Artificial intelligence approaches to medicinal chemistry are increasingly powerful but struggle to predict bioactive molecules. Here a machine learning model generates synthetically accessible mimetics of natural products, which are shown to be bioactive against the retinoid X receptor.

[1]  G. Schneider,et al.  Counting on Natural Products for Drug Design , 2016 .

[2]  J. Kirchmair,et al.  Data Resources for the Computer-Guided Discovery of Bioactive Natural Products , 2017, J. Chem. Inf. Model..

[3]  Gisbert Schneider,et al.  Scaffold hopping from synthetic RXR modulators by virtual screening and de novo design. , 2018, MedChemComm.

[4]  David Weininger,et al.  SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules , 1988, J. Chem. Inf. Comput. Sci..

[5]  Simon Saubern,et al.  New aryl/heteroaryl CN bond cross-coupling reactions via arylboronic acid/cupric acetate arylation , 1998 .

[6]  Petra Schneider,et al.  De Novo Design at the Edge of Chaos. , 2016, Journal of medicinal chemistry.

[7]  Petra Schneider,et al.  Privileged Structures Revisited , 2017, Angewandte Chemie.

[8]  Thorsten Meinl,et al.  KNIME - the Konstanz information miner: version 2.0 and beyond , 2009, SKDD.

[9]  J. Gasteiger,et al.  ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES , 1980 .

[10]  Gisbert Schneider,et al.  Computer-Assisted Discovery of Retinoid X Receptor Modulating Natural Products and Isofunctional Mimetics. , 2018, Journal of medicinal chemistry.

[11]  Gisbert Schneider,et al.  De Novo Design of Bioactive Small Molecules by Artificial Intelligence , 2018, Molecular informatics.

[12]  Makoto Inoue,et al.  Identification of a naturally occurring rexinoid, honokiol, that activates the retinoid X receptor. , 2010, Journal of natural products.

[13]  Lucia Altucci,et al.  Design of selective nuclear receptor modulators: RAR and RXR as a case study , 2007, Nature Reviews Drug Discovery.

[14]  Belén Vaz,et al.  Advances in drug design with RXR modulators , 2012, Expert opinion on drug discovery.

[15]  Petra Schneider,et al.  Generative Recurrent Networks for De Novo Drug Design , 2017, Molecular informatics.

[16]  Petra Schneider,et al.  Identifying the macromolecular targets of de novo-designed chemical entities through self-organizing map consensus , 2014, Proceedings of the National Academy of Sciences.

[17]  Peter Willett,et al.  Combination Rules for Group Fusion in Similarity‐Based Virtual Screening , 2010, Molecular informatics.

[18]  Li Li,et al.  Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode. , 2011, Journal of molecular biology.

[19]  Ewgenij Proschak,et al.  Nonacidic Farnesoid X Receptor Modulators. , 2017, Journal of medicinal chemistry.

[20]  Gerd Geisslinger,et al.  A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis. , 2017, Journal of medicinal chemistry.

[21]  Simon Saubern,et al.  New Aryl/Heteroaryl C—N Bond Cross-Coupling Reactions via Arylboronic Acid/Cupric Acetate Arylation. , 1998 .

[22]  R. Venkataraghavan,et al.  Atom pairs as molecular features in structure-activity studies: definition and applications , 1985, J. Chem. Inf. Comput. Sci..

[23]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[24]  Peter Ertl,et al.  Natural Product-likeness Score and Its Application for Prioritization of Compound Libraries , 2008, J. Chem. Inf. Model..

[25]  John Buckingham,et al.  Dictionary of natural products , 2014 .

[26]  Petra Schneider,et al.  Chemically Advanced Template Search (CATS) for Scaffold-Hopping and Prospective Target Prediction for ‘Orphan’ Molecules , 2013, Molecular informatics.

[27]  Gregor Eichele,et al.  International Union of Pharmacology. LXIII. Retinoid X Receptors , 2006, Pharmacological Reviews.

[28]  H. L. Morgan The Generation of a Unique Machine Description for Chemical Structures-A Technique Developed at Chemical Abstracts Service. , 1965 .

[29]  Roberto Todeschini,et al.  Matrix‐based Molecular Descriptors for Prospective Virtual Compound Screening , 2017, Molecular informatics.

[30]  B. Spiegelman,et al.  International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors , 2006, Pharmacological Reviews.

[31]  Gisbert Schneider,et al.  De novo Drug Design – Ye olde Scoring Problem Revisited , 2017, Molecular informatics.

[32]  Makoto Inoue,et al.  Identification of a naturally occurring retinoid X receptor agonist from Brazilian green propolis. , 2014, Biochimica et biophysica acta.

[33]  Gisbert Schneider,et al.  Scaffold hopping from natural products to synthetic mimetics by holistic molecular similarity , 2018, Communications Chemistry.

[34]  Markus Hartenfeller,et al.  De novo drug design. , 2010, Methods in molecular biology.

[35]  Thomas A. Halgren Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..

[36]  Ewgenij Proschak,et al.  Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery. , 2017, Journal of medicinal chemistry.